Below is an image of an Eli Lilly letter which informs doctors in the UK that Prozac is no longer authorized for use in (so-called) premenstrual dysphoric disorder (PMDD). For a larger view, please click on the image.
AHRP InfoMail Return to Home Page Return to InfoMail Media Coverage List MediaCoverage News Stories on Human ResearchProtection andCommentary by Vera Hassner Sharav April 22, 2002 ScientificMisconduct Notices FYI Scientific misconduct is a big problem undermining theintegrity of the scientific literature. Data falsification leads others toerroneous conclusions that may have…
AHRP InfoMail Return to Home Page Return to InfoMail Media Coverage List MediaCoverage News Stories on Human ResearchProtection andCommentary by Vera Hassner Sharav February 20, 2002 FYI How the Mental Health System hasImpeded Road to Recovery by Stripping Patients of their Humanity For those interested in gaining insight into the…
Public Comments Re: Smallpox Vaccine Trial on 2 to 5 Year Old Children The Code of Federal Regulations (45 CFR 46.407) requires that any experiment involving children which puts them at greater than minimal risk without a potential benefit to justify the risk, requires the Secretary of Health and Human…
AHRP Position Statement on Mental Health Screening – FDA Hearing Re: Drug Advertising Wed, 02 Nov 2005 FDA is holding public hearings (Nov 1, 2) Re:Â Direct-to-Consumer Promotion of Medical Products at: National Transportation Safety Board Boardroom and Conference Center 429 L’Enfant Plaza, SW., Washington, DC 2 Time: 9:00 –5:00….
DHHS Report: Contradicting itself on drug imports – OpEd Peter Rost Wed, 5 Jan 2005 Dr. Peter Rost, a Pfizer Vice-President of Marketing knows about the financial underpinnings of drug pricing. He has taken a consciencious public position (unsusual in that industry) because he believes the American public has a…
Topical tacrolimus and pimecrolimus: cancer, infections—"a clearly unfavorable benefit-risk ratio"— Prescrire International 2010 ; 19 (110) : 257 English edition.
